Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absent, Akkaraju, Alfasigma, Annex, Antitrust, assumption, automatically, circumstance, Clark, consummated, consummation, contemplated, County, detailed, Dickerson, dissemination, enable, ERP, frame, Haltman, Interstellar, inventory, Issuer, Jersey, ledger, legacy, organizational, pendency, professional, rescission, retention, rollforward, saving, seller, subsidiary, Supplementary, tender, tendered, usage, validly, voluntarily, waiting, Walsh, wholly
Removed:
lease, municipal
Financial report summary
?Competition
Bristol-Myers Squibb • Pfizer • Ionis Pharmaceuticals • Gilead Sciences • Amarin • Astrazeneca • Cymabay Therapeutics • Arena Pharmaceuticals • Durect • Gyre TherapeuticsManagement Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
- You should read the following discussion and analysis together with our condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”). This discussion and analysis contains forward-looking statements, which involve risks and uncertainties. As a result of many factors, such as those described under “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report, our actual results may differ materially from those anticipated in these forward-looking statements.
- We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (“PBC”) and severe alcohol-associated hepatitis (“sAH”), using our proprietary bile acid chemistry. Our first marketed product, Ocaliva® (obeticholic acid or “OCA”), is a farnesoid X receptor (“FXR”) agonist approved in the United States and other jurisdictions for the treatment of PBC in combination with ursodeoxycholic acid (“UDCA”) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.